DC
LTRN icon

Davenport & Co’s Lantern Pharma LTRN Stock Holding History

Davenport & Co’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.3K Hold
23,814
– – ﹤0.01% 1344
2026
Q1 		$32.6K Hold
23,814
– – ﹤0.01% 1296
2025
Q4 		$72.2K Sell
23,814
-2,000
-8% -$7.45K ﹤0.01% 1247
2025
Q3 		$112K Hold
25,814
– – ﹤0.01% 1211
2025
Q2 		$81.6K Hold
25,814
– – ﹤0.01% 1197
2025
Q1 		$91.4K Hold
25,814
– – ﹤0.01% 1162
2024
Q4 		$82.3K Sell
25,814
-28,000
-52% -$95.9K ﹤0.01% 1140
2024
Q3 		$197K Sell
53,814
-10,000
-16% -$41.2K ﹤0.01% 1111
2024
Q2 		$298K Buy
+63,814
New +$384K ﹤0.01% 950

Other funds holding LTRN

WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
EF
Entrust Financial Wayne, Pennsylvania $154M AUM
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
KFI
Key Financial Inc West Chester, Pennsylvania $611M AUM 21.11% 1-Year Est. Return

Davenport & Co's LTRN Position: Q2 2026 in Review

Davenport & Co held its Lantern Pharma (LTRN) position steady in Q2 2026 at 23,814 shares worth $99.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1344.

Davenport & Co first reported a position in LTRN in Q2 2024 and has held it in 9 quarters since. The position peaked at $298K in Q2 2024. 8 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Davenport & Co held 23,814 shares of Lantern Pharma worth $99.3K as of Q2 2026.
  • Davenport & Co left its Lantern Pharma share count unchanged in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #1344 holding.
  • Davenport & Co first reported a position in Lantern Pharma in Q2 2024 and has held it in 9 quarters since.
  • Davenport & Co's Lantern Pharma position peaked at $298K in Q2 2024.
  • 8 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.